Gilead Sciences layoffs, on the record
Every job cut, severance charge and restructuring Gilead Sciences reported in its annual reports, 2023 to 2025, quoted from the filings. Headcount went from approximately 18,000 to approximately 17,000.
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2023 | approximately 18,000 | December 31, 2023 |
| 10-K for 2024 | approximately 17,600 | December 31, 2024 |
| 10-K for 2025 | approximately 17,000 | December 31, 2025 |
Job cuts, severance and restructuring
Our summaryGilead recorded restructuring charges tied to changes in its manufacturing strategy, including a decision to stop using certain facilities, which led to full impairment of the related assets.
Word for word“During 2023, we incurred restructuring charges totaling $ 527 million primarily due to changes in our manufacturing strategy which included a decision to no longer utilize certain facilities.” 10-K for 2023
Our summaryRestructuring expenses tied to changes in its manufacturing strategy, including write-offs of certain manufacturing facilities and related inventories, reduced product gross margin.
Word for word“Product gross margin decreased to 75.9% in 2023, compared to 2022, primarily driven by higher intangible asset amortization expenses related to the pretreated HR+/HER2- metastatic breast cancer indication for Trodelvy following its approval in February 2023, restructuring expenses related to changes in our manufacturing strategy, which resulted in write-offs of certain manufacturing facilities, related inventories and other costs totaling $479 million, and product mix, partially offset by higher amortization of inventory step-up charges in 2022.” 10-K for 2023
Our summaryGilead incurred restructuring charges primarily tied to starting reductions in its commercial and R&D workforce.
Word for word“During 2024, we incurred restructuring charges of $ 188 million, primarily related to the initiation of reductions in our commercial and R&D workforce.” 10-K for 2024
Our summaryGilead recorded a liability for restructuring charges that it expects to mostly pay within the next 12 months.
Word for word“As of December 31, 2024, we have recorded a liability of $ 93 million on our Consolidated Balance Sheets associated with these restructuring charges, a majority of which we anticipate will be paid in the next 12 months.” 10-K for 2024
Our summaryGilead recorded 2023 restructuring charges tied to changes in its manufacturing strategy, including a decision to stop using certain facilities.
Word for word“During 2023, we incurred restructuring charges of $ 527 million primarily related to changes in our manufacturing strategy which included a decision to no longer utilize certain facilities.” 10-K for 2024
Our summaryGilead recorded restructuring charges in 2025 and 2024 mainly for workforce reductions.
Word for word“In 2025 and 2024, we incurred restructuring charges primarily related to reductions in our workforce.” 10-K for 2025
Our summaryGilead had a remaining restructuring liability at year end, most of which it expects to pay within 12 months.
Word for word“As of December 31, 2025, we had a remaining liability of $ 61 million on our Consolidated Balance Sheets associated with restructuring charges, a majority of which we anticipate will be paid in the next 12 months.” 10-K for 2025
Our summaryIn 2023 Gilead recorded restructuring charges tied to a change in manufacturing strategy and the end of use of certain facilities.
Word for word“In 2023, we incurred restructuring charges primarily related to changes in our manufacturing strategy which included a decision to n o longer utilize certain facilities.” 10-K for 2025
| Fiscal year ended | Restructuring charges |
|---|---|
| 2023-12-31 | $527 million |
| 2024-12-31 | $188 million |
| 2025-12-31 | $138 million |
Gilead Sciences has filed no restructuring notice (Form 8-K, Item 2.05) since 2016. Companies file one only for a cut they judge material, so many announced layoffs never appear as one. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Gilead Sciences’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-24. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.